Mon Sep 16 15:52:23 UTC 2024: ## Protalix BioTherapeutics CEO to Present at Life Sciences Investor Forum
**CARMIEL, ISRAEL – September 16, 2024** – Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company specializing in plant-based protein production, announced that CEO Dror Bashan will present at the Life Sciences Investor Forum on September 19, 2024.
The event, hosted by VirtualInvestorConferences.com, will be held online and allow for real-time interaction between investors and Protalix. Attendees can ask questions directly to Bashan during the presentation. A recording of the presentation will be available for those unable to attend live.
Protalix, a pioneer in plant cell-based protein expression, has secured FDA approval for its first product, taliglucerase alfa, a treatment for Gaucher disease. The company’s second product, Elfabrio, was approved by both the FDA and the European Medicines Agency in May 2023.
Protalix is currently developing several other potential treatments, including PRX-115 for uncontrolled gout and PRX-119 for NETs-related diseases.
The Life Sciences Investor Forum provides a platform for publicly traded companies to connect with investors. The event offers features such as one-on-one meetings and dynamic video content to facilitate engagement and communication.
First Piper 